Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

tion had prior anti-TNFalpha failure; 26 percent were primary failures. In addition, approximately 30 percent had failed at least two TNF antagonists. At week six, clinical remission was seen in 14.5 percent of patients randomized to vedolizumab versus 6.8 percent who received placebo (p=0.02). At six weeks, no significant difference was observed in CDAI-100 response between the vedolizumab and placebo groups (31.4 percent versus 25.7 percent, respectively [p=0.23]).  

The maintenance arm of GEMINI II assessed the efficacy and safety of vedolizumab for maintaining response and remission in patients with moderately to severely active CD with evidence of clinical response after two 300 mg IV induction doses of vedolizumab. Patients responding (greater than or equal to 70-point decrease in CDAI from baseline) at week six to induction treatment with vedolizumab were randomized to vedolizumab 300 mg IV every four weeks, every eight weeks, or placebo for up to 52 weeks. The primary endpoint was clinical remission at week 52, while the secondary endpoints were CDAI-100 response, glucocorticoid-free remission at week 52, and durable clinical remission (clinical remission at greater than or equal to 80 percent of visits including the final visit) at week 52. Of the 1,115 patients who received induction treatment, 461 met response criteria at six weeks (ITT population) and were randomized to receive vedolizumab every four weeks (n=154) or eight weeks (n=154), or placebo (n=153). At week 52, remission was seen in 39.0 percent and 36.4 percent of patients randomized, respectively, to vedolizumab every eight weeks or every four weeks versus 21.6 percent of the patients receiving placebo (p<0.001, p=0.004, respectively). CDAI-100 response was seen in 43.5 percent and 45.5 percent of patients randomized, respectively, to vedolizumab every eight weeks or every four weeks versus 30.1 percent of patients receiving placebo at week 52 (p=0.01, p=0.005 respectively). Gluc
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" ... analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in ... Vials, and IV solutions), Solid Dosage Forms (Tablets and ... Gels, Creams & Ointments). The report provides ...
(Date:8/19/2014)... 2014  AVIA – a provider-led accelerator that puts ... problems in healthcare ­– announces Sutter Health, a not-for-profit ... as the most recent addition to the AVIA Innovator ... AVIA,s inaugural cohort focused helping patients navigate the healthcare ... a patient,s providers so they work as a larger ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... measurement technology, today announced the addition of the EmBand 24™ to the EmBand™ family of neuromarketing measurement devices. , ... , , ... ... ...
... , ATLANTA , March 22 Fulcrum Ventures announced today that they invested $1.25 ... solution for kit design, production, client supply management and patient specimen tracking.  Based in Columbus, Georgia , ... ... , ...
Cached Medicine Technology:EmSense Announces Release of Revolutionary EmBand 24(TM) 2EmSense Announces Release of Revolutionary EmBand 24(TM) 3EmSense Announces Release of Revolutionary EmBand 24(TM) 4Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 2Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 3
(Date:8/20/2014)... easier to predict both breast cancer relapses and ... unique gene. The newly found marker could help ... a treatment regimen that is more effective. The ... A*STAR,s Institute of Molecular and Cell Biology (IMCB), ... Singapore) at the National University of Singapore (NUS). ...
(Date:8/20/2014)... It’s no secret that millions of Americans are ... on Drug Abuse, nearly 24 million Americans are using ... is the fact that the total number of users ... in a struggle with substance abuse often feel there ... newly-redesigned AbuseTreatmentCenters.net has released updated lists of substance ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
(Date:8/20/2014)... Botanica Day Spa has ... new and popular stem cell line from Pevonia®, ... wrinkles and naturally repairs the skin. The spa ... service by offering clients a complimentary dermaplaning session ... , Pevonia® continues to be a global leader ...
(Date:8/20/2014)... car at home and getting to work by walking, cycling ... study indicates. Researchers looked at thousands of people in ... and 72 percent of women drove to work, 10 percent ... and 14 percent of men and 17 percent of women ... more and had higher levels of body fat than those ...
Breaking Medicine News(10 mins):Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Want to Stay Slim? Leave the Car at Home 2
... 7 (HealthDay News) -- In November, the U.S. Food and ... the treatment of breast cancer. But, a new study ... with a specific type of aggressive breast tumor when used ... (bevacizumab) had been approved in the United States in 2008 ...
... the fierce national debate over a new federal law ... widely assumed that private health insurance can do a ... U.S. government. But a first-of-its-kind analysis of newly ... comes to infants covered by insurance. Among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) ... with low-risk prostate cancer, a new draft report released ... concluded that research on the safety of "active surveillance" ... men opt for surgery or other treatments that can ...
... have altered natural bioelectrical communication among cells to directly ... at a particular location within a vertebrate organism. Using ... biologists at Tufts University,s School of Arts and Sciences ... of the head area. The researchers achieved most ...
... California,s low-income seniors with disabilities are struggling to remain in ... and may be slashed even further, according to a new ... with support from The SCAN Foundation. Should ... to In-Home Supportive Services (IHSS) on Dec. 15, as proposed ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 7 ... through strategically placed "seeds" had double the risk of a ... their entire breast, new research finds. This type ... side effects, including infection, according to the study. "We ...
Cached Medicine News:Health News:Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study 2Health News:Public health insurance offers insured infants better, less costly care than private plans 2Health News:Public health insurance offers insured infants better, less costly care than private plans 3Health News:Public health insurance offers insured infants better, less costly care than private plans 4Health News:Public health insurance offers insured infants better, less costly care than private plans 5Health News:Active Surveillance May Benefit Men With Low-Risk Prostate Cancer 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 4Health News:Targeted Radiation May Not Be Better for Breast Cancer 2Health News:Targeted Radiation May Not Be Better for Breast Cancer 3